Abstract Library

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,

#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors

Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Atsuko K

Authors: Kasajima A, Pavel M, Darb-Esfahani S, Stenzinger A, Sasano H,

Keywords: neuroendocrine tumor, proliferation index ,